Pharmaceutical - isavuconazole

Filter

Current filters:

isavuconazole

Popular Filters

Astellas' isavuconazole NDA accepted by US FDA

Astellas' isavuconazole NDA accepted by US FDA

08-09-2014

The US Food and Drug Administration has accepted a New Drug Application filing by Japanese drug major…

Astellas PharmaFungal diseasesInvasive aspergillosisInvasive mucormycosisisavuconazoleOncologyPharmaceuticalRegulationUSA

Astellas amends license deal for isavuconazole with Basilea

01-03-2014

Japanese drug major Astellas Pharma has amended the license, co-development and co-promotion agreement…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaCanadaisavuconazoleLicensingNorth AmericaPharmaceuticalUSA

Astellas’ antifungal study reports positive results

30-09-2013

Astellas Pharma has announced positive topline data from the Phase III invasive aspergillosis study (SECURE)…

Asia-PacificAstellas PharmaBasilea PharmaceuticaDermatologicalsisavuconazolePharmaceuticalResearch

Basilea updates on isavuconazole development

17-07-2013

Switzerland-based Basilea Pharmaceutica Ltd. (SIX: BSLN) provided an update today (July 17) on the Phase…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaisavuconazolePharmaceuticalResearch

GlaxoSmithKline gets global rights to Basilea's Toctino

12-06-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) says that its dermatology-focussed subsidiary Stiefel has…

Basilea PharmaceuticaceftobiproleDermatologicalsGlaxoSmithKlineisavuconazoleLicensingPharmaceuticalResearchStiefelToctino

Back to top